Trials / Completed
CompletedNCT04586439
A Study of JNJ-73763989 in Healthy Chinese Adult Participants
A Randomized, Open-Label, Parallel, Single Dose Study to Investigate Pharmacokinetics, Safety, and Tolerability of JNJ-73763989 in Healthy Chinese Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the single-dose Pharmacokinetics of JNJ-73763976 and JNJ-73763924 following a subcutaneous (SC) injection of JNJ-73763989 (JNJ-3989) in healthy Chinese adult participants at 2 different doses, Dose 1 (Panel A) or Dose 2 (Panel B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-73763989 | JNJ-73763989 will be administered (high or low dose) as single SC injection. |
Timeline
- Start date
- 2020-11-24
- Primary completion
- 2021-02-18
- Completion
- 2021-02-18
- First posted
- 2020-10-14
- Last updated
- 2021-03-08
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04586439. Inclusion in this directory is not an endorsement.